Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who's Online
There are currently, 96 guest(s) and 11 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!


ThisIsMS.com :: View topic - Testimony by Dr John Richert
 Forum FAQForum FAQ   SearchSearch   UsergroupsUsergroups   ProfileProfile   Log in to check your private messagesLog in to check your private messages   Log inLog in 


Testimony by Dr John Richert

 
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Tysabri (Antegren or Natalizumab)
View previous topic :: View next topic  
Author Message
bromley
Family Elder


Joined: Sep 11, 2004
Posts: 1838

PostPosted: Mon Mar 06, 2006 1:28 pm    Post subject: Testimony by Dr John Richert Reply with quote

A couple of weeks ago I posted part of an e-mail I had received from Dr John Richert, Vice Presdient of Research at the NMSS.

Attached is his testimony to the FDA about Tysabri.

Apologies if it has already been posted.

Ian

http://www.nationalmssociety.org/tysabri_richerttestimony.asp
Back to top
View user's profile Send private message
Brownsfan
Family Member


Joined: Aug 26, 2005
Posts: 90

PostPosted: Mon Mar 06, 2006 2:24 pm    Post subject: Reply with quote

"In this survey, questions about acceptable degrees of risk were phrased in a manner such as: Would you wish to take this drug if the risk of dying from PML within 3 years is one in a thousand, or 1%, or 10 %, and so on, right up to a 100% risk of dying from PML. The responses were spread relatively evenly throughout the range, without a cut-off at any particular degree of risk."

Does this imply that some bonehead responded to the survey by saying he/she would take tysabri if the risk of dying from PML was 100%?


"It is likely that our frame of reference for MS drugs will need to change to be more in line with the toxicity risks that are recognized in the treatment of other autoimmune diseases."

Translation - we kill people with other drugs, what's all the fuss?
Back to top
View user's profile Send private message
amelia
Family Elder


Joined: Feb 10, 2005
Posts: 309
Location: grenada, ms

PostPosted: Tue Mar 07, 2006 9:52 am    Post subject: Reply with quote

Quote:
Translation - we kill people with other drugs, what's all the fuss?


This has been my gripe all along. Many other drugs kill people. And yes there is a risk with Tysabri. But what does not have a risk out there. If you don't want to take the risk and you aren't going to take Tysabri, get out of the way of all the people who want to take it.
No risk taken; Nothing gained.
Back to top
View user's profile Send private message Send e-mail Visit poster's website
OddDuck
Contributing Author


Joined: Jun 20, 2004
Posts: 1040
Location: Tennessee

PostPosted: Sun Apr 02, 2006 9:56 am    Post subject: Reply with quote

Quote:
Determining the relative risks and benefits for Tysabri is a complicated matter. There are data that are being considered by the Advisory Panel that have not generally been in the public domain.


Yeah, well, don't overlook THAT above statement, either! How much does the public really know in order to be able to make a truly informed decision on whether to take a certain drug or not? How can you make an informed decision if you really don't know exactly what the real risk even IS?

At least the NMSS NOW is taking my advice and staying NEUTRAL! It's about time!
Back to top
View user's profile Send private message
OddDuck
Contributing Author


Joined: Jun 20, 2004
Posts: 1040
Location: Tennessee

PostPosted: Sun Apr 02, 2006 10:02 am    Post subject: Reply with quote

Ok...UPDATE!

Anyone seen this yet? Apologies if it has already been posted, but note the criteria that will come along with prescribing Tysabri.

amelia........Note in this, also, where it says it will be prescribed ONLY to RRMS patients.

http://www.nationalmssociety.org/tysabri_march8.asp
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    ThisIsMS.com Forum Index -> Tysabri (Antegren or Natalizumab) All times are GMT - 6 Hours
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum





Personal Stories about millions of life experience--including multiple sclerosis support, lupus support, depression support . Built by the This is MS team.

Anonymous Confessions | Dream Dictionary
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.


Visit our sister site dedicated to Inflammatory Bowel Disease: This is IBD


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002 by thisisMS.com.
PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Page Generation: 0.23 Seconds